Aurora Ignites Global Expansion with Whistler Cannabis Co. Brand Debut in Australia

Rhea-AI Summary

Aurora Cannabis (NASDAQ:ACB) has announced the launch of its premium brand Whistler Cannabis Co. in Australia, marking a significant expansion of its global medical cannabis footprint. The company will introduce two high-potency cultivars: Ginger Breath (32% THC) and Critical Diesel (28% THC), both available in 10g formats.

Whistler Cannabis Co., established in 2013, produces premium craft cannabis at Aurora's state-of-the-art Aurora Alpine facility in Pemberton Valley, British Columbia. The brand is known for its small-batch production, proprietary genetics, and meticulous hand-trimming process that preserves trichomes containing essential cannabinoids and compounds.

Insights

Global Cannabis Market Analyst

Aurora's expansion into Australia with premium Whistler brand signals strategic global growth in medical cannabis markets with high-THC products.

Aurora Cannabis is strategically expanding its global footprint by launching its premium Whistler Cannabis Co. brand in the Australian medical cannabis market. This expansion leverages Aurora's established Canadian cultivation expertise and introduces high-potency products to the growing Australian patient base.

The company is entering with two notably high-potency cultivars - Ginger Breath with 32% THC and Critical Diesel with 28% THC. These potency levels are significantly above average market offerings, positioning Aurora at the premium end of the Australian medical cannabis spectrum. Both products are being offered in 10g quantities, targeting regular medical cannabis patients.

This launch aligns with Aurora's international growth strategy, utilizing their EU and TGA GMP certified production capabilities - regulatory certifications that are essential for pharmaceutical-grade cannabis exports. The company appears to be executing a methodical global expansion by exporting established Canadian brands rather than developing market-specific offerings.

The Australian medical cannabis market represents a significant opportunity as one of the faster-growing international markets. By introducing craft cannabis with proprietary genetics and specialized production methods (hang-dried, hand-trimmed), Aurora is differentiating from standardized mass-production approaches prevalent in pharmaceutical cannabis.

This expansion should be viewed as part of Aurora's broader strategy to diversify revenue streams beyond the competitive Canadian market, potentially improving margin profiles through premium positioning in international markets where competition may be less intense and regulatory barriers create market entry advantages for established players.

Canada's Largest Medical Cannabis Company to Launch Two High-Potency Cultivars, Expanding Patient Choice in Australia

EDMONTON, ALBERTA, Aug. 12, 2025 /PRNewswire/ - Aurora Cannabis Inc. (NASDAQ: ACB) (TSX: ACB), the Canadian-based leading global medical cannabis company, announces the launch of Whistler Cannabis Co. in Australia. As one of Canada's original cannabis brands, with a proud history of growing premium, indoor craft cannabis, this unique brand offers Australian patients a true Canadian cannabis experience.

"Whistler is a tried-and-true brand in the Canadian market," said Andre Jerome, Executive Vice President of Global Business Development at Aurora. "We're excited to now extend its legacy, and our Canadian cultivation expertise, to Australian patients. This milestone underscores our commitment to global growth and our patient-first approach."

First developed in 2013, Whistler is cultivated in Aurora's state-of-the-art facility, Aurora Alpine, located in Pemberton Valley, British Columbia. Produced in small batches using top-tier, proprietary genetics, each plant is harvested at its peak ensuring consistent quality. The premium craft medical cannabis flower is hang-dried and hand-trimmed, undergoing a slow, controlled drying process to preserve delicate trichomes – which contain most of the plant's aroma, cannabinoids, and active compounds.

The first two Whistler Cannabis Co. products to launch in Australia are:

• Ginger Breath – 32% THC, Indica, 10g, bred from '91 Royale and Driftwood Diesel genetics, and has a terpene profile of Caryophyllene, Pinene, and Linalool. This cultivar has a complex aroma profile of spicy-ginger, gasoline, chai and citrus.
• Critical Diesel – 28% THC, Sativa, 10g, bred from Critical Sensi Star and Driftwood Diesel lineages, and has a terpene profile of Caryophyllene, Pinene, and Myrcene. This cultivar has a fruity aroma profile of cherry, grape, strawberry, vanilla and gasoline.

Aurora has established trusted leadership in Canadian and international medical cannabis markets through robust regulatory expertise, investment in technology and distribution, and an unwavering commitment to science. A strict adherence to EU and TGA GMP certified production enables the company's success in international markets.

About Aurora Cannabis Inc.

Aurora is opening the world to cannabis, serving both the medical and consumer markets across Canada, Europe, Australia and New Zealand. Headquartered in Edmonton, Alberta, Aurora is a pioneer in global cannabis, dedicated to helping people improve their lives. The Company's adult-use brand portfolio includes Drift, San Rafael '71, Daily Special, Tasty's, Being and Greybeard. Medical cannabis brands include MedReleaf, CanniMed, Aurora and Whistler Medical Marijuana Co., as well as international brands, Pedanios, IndiMed and CraftPlant. Aurora also has a controlling interest in Bevo Farms Ltd., North America's leading supplier of propagated agricultural plants. Driven by science and innovation, and with a focus on high-quality cannabis products, Aurora's brands continue to break through as industry leaders in the medical, wellness and adult recreational markets wherever they are launched. Learn more at www.auroramj.com and follow us on X and LinkedIn.

Aurora's common shares trade on the NASDAQ and TSX under the symbol "ACB".

Forward Looking Information  

This news release includes statements containing certain "forward-looking information" within the meaning of applicable securities law ("forward-looking statements"). Forward-looking statements are frequently characterized by words such as "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed" and other similar words, or statements that certain events or conditions "may" or "will" occur. Forward-looking statements made in this news release include, but are not limited to, statements regarding the launch of the Company's Whistler Cannabis Co. brand in Australia, including related to product potency and availability, and statements regarding the Company's commitment to continued growth and success in global markets.

These forward-looking statements are only predictions. Forward looking information or statements contained in this news release have been developed based on assumptions management considers to be reasonable. Material factors or assumptions involved in developing forward-looking statements include, without limitation, publicly available information from governmental sources as well as from market research and industry analysis and on assumptions based on data and knowledge of this industry which the Company believes to be reasonable. Forward-looking statements are subject to a variety of risks, uncertainties and other factors that management believes to be relevant and reasonable in the circumstances could cause actual events, results, level of activity, performance, prospects, opportunities or achievements to differ materially from those projected in the forward-looking statements. These risks include, but are not limited to, the magnitude and duration of potential new or increased tariffs imposed on goods imported from Canada into the United States; the ability to retain key personnel, the ability to continue investing in infrastructure to support growth, the ability to obtain financing on acceptable terms, the continued quality of our products, customer experience and retention, the development of third party government and non-government consumer sales channels, management's estimates of consumer demand in Canada and in jurisdictions where the Company exports, expectations of future results and expenses, the risk of successful integration of acquired business and operations, management's estimation that SG&A will grow only in proportion of revenue growth, the ability to expand and maintain distribution capabilities, the impact of competition, the general impact of financial market conditions, the yield from cannabis growing operations, product demand, changes in prices of required commodities, competition, and the possibility for changes in laws, rules, and regulations in the industry, epidemics, pandemics or other public health crises and other risks, uncertainties and factors set out under the heading "Risk Factors" in the Company's annual information from dated June 17, 2025  (the "AIF") and filed with Canadian securities regulators available on the Company's issuer profile on SEDAR+ at www.sedarplus.com and filed with and available on the SEC's website at www.sec.gov. The Company cautions that the list of risks, uncertainties and other factors described in the AIF is not exhaustive and other factors could also adversely affect its results. Readers are urged to consider the risks, uncertainties and assumptions carefully in evaluating the forward-looking statements and are cautioned not to place undue reliance on such information. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable securities law.

View original content to download multimedia:https://www.prnewswire.com/news-releases/aurora-ignites-global-expansion-with-whistler-cannabis-co-brand-debut-in-australia-302527426.html

SOURCE Aurora Cannabis Inc.

FAQ

What products is Aurora Cannabis (ACB) launching in Australia?

Aurora is launching two Whistler Cannabis Co. products: Ginger Breath (32% THC, Indica, 10g) and Critical Diesel (28% THC, Sativa, 10g).

Where is Whistler Cannabis Co.'s product manufactured?

Whistler Cannabis Co. products are manufactured at Aurora's Aurora Alpine facility in Pemberton Valley, British Columbia, Canada.

What are the THC levels of Aurora's new Australian cannabis products?

The two products have high THC levels: Ginger Breath at 32% THC and Critical Diesel at 28% THC.

How does Aurora ensure quality for its Australian cannabis products?

Aurora maintains quality through small-batch production, proprietary genetics, hand-trimming, and adherence to EU and TGA GMP certified production standards.